Abbott Laboratories is Challenging Biotech Drug Copies, Protects Humira's Secrets
Published: Jun 25, 2012
Abbott Laboratories is challenging a provision in the federal health overhaul meant to usher in a new era of affordable medicines. If the challenge succeeds, less-expensive versions of complex biologic drugs couldn't go on sale in the U.S. for years, and consumers may never have access to facsimiles of existing treatments such as Abbott's rheumatoid arthritis therapy Humira, which had $3.4 billion in U.S. sales last year and is projected to be the world's No. 1-selling drug this year.